|
TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity. |
|
|
Employment - Neogenomics Laboratories |
Stock and Other Ownership Interests - Cytodyn; MindMed |
|
|
Employment - Neogenomics Laboratories |
|
|
Employment - Neogenomics Laboratories |
|
|
Employment - Neogenomics Laboratories |
Stock and Other Ownership Interests - Neogenomics Laboratories |
|
|
No Relationships to Disclose |
|
|
Employment - Neogenomics Laboratories |
Stock and Other Ownership Interests - Neogenomics Laboratories |
|
|
Employment - Neogenomics Laboratories |
Stock and Other Ownership Interests - Neogenomics Laboratories |
|
|
Employment - Neogenomics Laboratories |
Leadership - Neogenomics Laboratories |
Stock and Other Ownership Interests - Neogenomics Laboratories |
Consulting or Advisory Role - Bayer; Lilly; Merck; Novartis; Roche; Thermo Fisher Scientific |
Speakers' Bureau - Bayer; Lilly; Merck; Novartis; Roche; Thermo Fisher Scientific |
Research Funding - Roche; Ventana Medical Systems |
|
|
Employment - Neogenomics Laboratories |